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a patient’s multiple prior admissions. Our objective is to
develop a model that predicts future admissions based on
left ventricular ejection fraction (LVEF) and the occur-
rence of a CHF admission in the preceding quarter.
Another objective is to use this model to examine, in a
managed care setting, the cost-beneﬁt of the following
CHF management strategies: ACE inhibitor therapy, beta
blocker therapy, CHF disease management, and inten-
sive case management. METHODS: We constructed a
Markov model to project the medical and non-medical
costs for a cohort of CHF patients in a commercially
insured population. The model deﬁnes four disease states
based on LVEF status (normal vs. low) and a prior admis-
sion (yes vs. no) in the preceding quarter. The probabil-
ity of a future admission depends on the patient’s disease
state as well as age and gender. Plan-speciﬁc CHF admis-
sion probabilities were calibrated using claims analyses.
Each intervention is assumed to change health service 
utilization patterns and improve survival. Cost-beneﬁt 
is expressed as net savings in medical and non-medical
costs. RESULTS: For a population of 100,000 commer-
cially insured individuals, CHF case rate and medical
costs are predicted to increase steadily over the next 5
years. Intensive case management appears to be the most
cost-beneﬁcial intervention, with an estimated per
member per month (PMPM) net savings of $0.11 in the
ﬁrst year. Beta blocker therapy is expected to save $0.08
in the ﬁrst year, while ACE inhibitors and CHF disease
management show net positive savings starting year 2. All
interventions remain cost-beneﬁcial when non-medical
savings are eliminated from the analyses. CONCLU-
SIONS: The four CHF management strategies modeled
are not only effective in improving clinical outcomes; they
are also predicted to be cost-beneﬁcial in a managed care
setting.
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OBJECTIVES: Coronary artery disease (CAD) is the
second most important disease resulting in mortality 
in Hong Kong. The most severe manifestation is acute
myocardial infarction (AMI). Both treatment and cardiac
rehabilitation for AMI are costly. Cost of management of
AMI is an important baseline information for better plan-
ning under scarce allocation of medical resources. The
present study aims to evaluate the cost of management of
explicit Q-wave AMI in a local public hospital in Hong
Kong. METHODS: A retrospective study was performed
on patients admitted to the United Christian Hospital.
The study cohort consisted of one hundred patients
admitted to Coronary Care Unit who were aged 18 year
old or above with a diagnosis of Q-wave AMI from 1
January 2000 to 31 December 2000. Cost items studied
included hospital stay, outpatient clinic visits, diagnostic
tests, medications, and percutaneous coronary interven-
tions. RESULTS: Ninety-eight case notes (2 case note
were incomplete) were evaluated. The average annual
medical cost per patient for AMI management in this 
population was USD $8990 (1 US $ = 7.8HK$). The total
annual cost per patient per year increased with the com-
plexity of the disease—from USD $7320 for non-fatal MI
without procedure, USD $10,963 for non-fatal MI with
angiogram, to USD $12,030 for non-fatal MI with pro-
cedure. Based on the local epidemiological data, the
prevalence rate of CAD is 2.2% and assuming 3% of
patients may experience AMI with medical care, the esti-
mated total cost of AMI management in Hong Kong was
USD $45 million per year, or 0.5% of the 2000–01
healthcare expenditure. CONCLUSIONS: The present
study provides information of the cost of AMI manage-
ment in Hong Kong. It conﬁrms that AMI management
is a signiﬁcant burden to the healthcare budget. Public
awareness on CAD and implementation of appropriate
health measures should be reinforced.
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OBJECTIVE: To determine the impact of acute rheumatic
fever (ARF) and chronic rheumatic heart disease (CRHD)
on hospital expenditure in the United States. METHODS:
This study analyzed data from the Healthcare Cost and
Utilization Project (2000) funded by the Agency for
Healthcare Research and Quality. Hospitalizations due 
to ARF and CRHD were identiﬁed using ICD-9 codes
390–398 as principal diagnoses. RESULTS: In 2000,
there were approximately 1226 and 44,659 hospitaliza-
tions due to ARF and CRHD, respectively. Females
accounted for about 58% of all hospitalizations due to
ARF, and 63% due to CRHD. The elderly aged 65 years
and older accounted for 74% of the hospitalizations due
to CRHD, followed by adults aged 35–64 years (24%).
The two most common comorbid conditions associated
with CRHD were atrial ﬁbrillation (49%) and hyperten-
sion (34%). The two most common procedures per-
formed during CRHD hospitalizations were
extracorporeal circulation for open heart surgery (10%)
and diagnostic ultrasound of the heart (7%). The mean
(and median) length of hospital stay for ARF and CRHD
was 7.5 (5) and 7.9 (6) days, respectively. Average charge
per hospital stay was about $29,500 for ARF and
